Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On March 31, 2025, Dogwood Therapeutics, Inc. announced financial results for 2024 and provided a business update.</li><li>The company recently dosed the first patient in the Halneuron Chemotherapy Induced Neuropathic Pain (CINP) Phase 2b trial.</li><li>We anticipate interim data in the fourth quarter of 2025.</li></ul>

On March 31, 2025, Dogwood Therapeutics, Inc. announced financial results for 2024 and provided a business update.The company recently dosed the first patient in the Halneuron Chemotherapy Induced Neuropathic Pain (CINP) Phase 2b trial.We anticipate interim data in the fourth quarter of 2025.

DWTX: Interim Data for Phase 2b Trial in 4Q25 